





UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/767,424	01/22/2001	Sara L. Zaknoen	OC01121K	9553
24265 7	590 02/25/2002			
SCHERING-	PLOUGH CORPOR	EXAMINER		
2000 GALLOF	ARTMENT (K-6-1, 1) PING HILL ROAD	HUFF, SHEELA JITENDRA		
KENILWORT	H, NJ 07033-0530		ART UNIT	- PAPER NUMBER
			1642	<del></del>
			DATE MAILED: 02/25/2002	!

Please find below and/or attached an Office communication concerning this application or proceeding.

•		Applicati	an No	Applicant(a)		
Office Action Summary				Applicant(s)		
		09/767,4	24	ZAKNOEN, SARA L.		
		Examine		Art Unit		
		Sheela J		1642		
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status 1) <u></u> ☐	Responsive to communication(s) filed on					
2a)□						
3)	/ <b>-</b>					
Disposition of Claims						
. 4)⊠ Claim(s) <u>1-22</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠	Claim(s) <u>1-22</u> is/are rejected.					
7)	Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/or election requirement.						
Application	on Papers					
9)☐ The specification is objected to by the Examiner.						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
	Applicant may not request that any objection to the					
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12)⊠ The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
<ul> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>						
14)⊠ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
<ul> <li>a) ☐ The translation of the foreign language provisional application has been received.</li> <li>15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.</li> </ul>						
Attachment(s)						
2) Notice	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	].		(PTO-413) Paper No(s) Patent Application (PTO-152)		

Art Unit: 1642

#### **DETAILED ACTION**

Claims 1-22 are pending.

## Information Disclosure Statement

The IDS filed 6/5/01 has been considered and an initialed copy of the PTO-1449 is enclosed.

# **Priority**

Applicant has priority to provisional application 60/177624 filed 1/24/00.

#### Oath/Declaration

The oath or declaration is defective. A new oath or declaration in compliance with 37 CFR 1.67(a) identifying this application by application number and filing date is required. See MPEP §§ 602.01 and 602.02.

The oath or declaration is defective because:

The declaration states that the provisional application was filed on 1/18/01. The provisional application was filed 1/24/00 not 1/18/01.

# Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Art Unit: 1642

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 1-22 are rejected under 35 U.S.C. 103(a) as being unpatentable over WO 97/12630 in view of Ragab US 6346524 (priority to 3/30/99) and Kline US 6180096 (which has priority to 3/26/98) or WO 95/13090.

WO 97/12630 discloses the combination therapy of cancer using temozolomide and interferon alpha 2b. The concentration of temozolomide ranges from 50-400 mg/m² with a daily dose administered over a 2-10 day period and can be administered in repeated cycles of 28-42 days. The concentration of interferon alpha 2b ranges from 1 million to 25 million IU per m². (see pages 3-5).

The only differences between the instant invention and the reference is the use of PEG<sub>12000</sub>-interferon alpha 2b, the specific concentrations of PEG<sub>12000</sub>-interferon alpha 2b and the formation of a kit.

Ragab discloses a dosing cycle of temozolomide of daily administrations for 5-25 days (at 40-150mg/m²/day) followed by a rest period of 4-15 days (abstract).

Kline discloses at PEG stabilizes interferon alpha during lyophilization and specifically exemplifies PEG 12000 and interferon alpha 2b (see entire reference).

Art Unit: 1642

WO 95/13090 discloses the formation of long-acting alpha interferon compositions using PEG and specifically discloses the use of using PEG with a MW ranging form 2000-12,500 (see page 6, lines 18-21 and page 2, lines 25+).

Thus, in view of the fact that PEG 12000 stabilizes interferon alpha 2b during lyophilization and that PEG in the range of 2000-12500 creates a long-acting alpha interferon, it would have been obvious to one of ordinary skill in the art at the time of applicant's invention to use interferon alpha 2b linked to PEG 12000 to form a more stable, long-acting interferon alpha 2b. The formation of a kit using known components is within the purview of one skilled in the art. Furthermore, the dosing cycle of temozolomide of daily administrations for 5-25 days (at 40-150mg/m²/day) followed by a rest period of 4-15 days is obvious in view of Ragab. Further optimization of dosages and dosing regimes is within the purview of one skilled in the art.

## Conclusion

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sheela J Huff whose telephone number is 703-305-7866. The examiner can normally be reached on M,Th 5:30 am-2:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa can be reached on 703-308-3995. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4242 for regular communications and 703-308-4242 for After Final communications.

Art Unit: 1642

Page 5

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

Sheela J Huff
Primary Examiner
Art Unit 1642

sjh February 21, 2002